Literature DB >> 11411801

Chronic treatment with amlodipine modulates adrenocortical angiotensin II receptors in spontaneously hypertensive rats.

M Kishida1, F Otsuka, T Ogura, H Kataoka, Y Nakamura, T Yamauchi, M Takahashi, K Yokota, Y Mimura, H Makino.   

Abstract

We investigated the effects of long-term treatment with calcium-antagonist, amlodipine, on angiotensin II receptors in the adrenal cortex of spontaneously hypertensive rats (SHR). Seven-week-old male SHR were treated with oral amlodipine (10 mg/kg/day) or vehicle (saline) for four weeks. Age-matched normotensive Wistar-Kyoto (WKY) rats were treated with the vehicle similar to control SHR. Systolic blood pressure (SBP) showed time-dependent increase in SHR but not in WKY rats, while amlodipine treatment significantly reduced the high SBP in SHR. Plasma renin activity was serially increased in SHR, which was further enhanced by amlodipine treatment. But the plasma aldosterone level which was increased in SHR was not changed by amlodipine. Competitive reverse transcriptase-polymerase chain reaction showed that the level of adrenocortical angiotensin II type 1 receptor (AT1R) mRNA progressively decreased in vehicle-treated SHR compared to WKY rats and that 4-week course of amlodipine treatment significantly increased AT1R mRNA in SHR to levels comparable to those in WKY rats. Amlodipine treatment reduced the level of adrenocortical angiotensin II type 2 receptor (AT2R) mRNA in SHR from 8 weeks of age. Thus, chronic amlodipine treatment differently modulates both adrenocortical AT1R and AT2R in SHR in a possibly direct manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11411801     DOI: 10.1016/s0024-3205(01)01071-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  1 in total

1.  Angiotensin II Type 1 Receptor Gene A1166C Polymorphism Was Not Associated With Acute Coronary Syndrome in an Iranian Population.

Authors:  Navid Delshad; Majid Ghayour-Mobarhan; Hamed Mirzaei; Kamal Razavi-Azarkhiavi; Mohsen Moohebati; Mitra Hassany; Jamal Kasaian; Mohammad Reza Etemadzadeh; Maryam Sadat Alavi; Javad Behravan
Journal:  Iran Red Crescent Med J       Date:  2016-07-09       Impact factor: 0.611

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.